

**Baxter International Inc.**  
**Key Product Line Sales**  
**Period Ending March 31, 2004**  
(unaudited)

(\$ in millions)	Q1 2004	Q1 2003	% Growth
<b>BioScience</b>			
Recombinants	\$ 292	\$ 244	19%
Plasma Proteins <sup>1</sup>	238	229	4%
Antibody Therapy	80	67	19%
Transfusion Therapies	140	134	4%
Other <sup>2</sup>	60	66	(7%)
<b>Total BioScience</b>	<b>\$ 810</b>	<b>\$ 740</b>	<b>9%</b>
<b>Medication Delivery</b>			
IV Therapies <sup>3</sup>	\$ 282	\$ 248	14%
Drug Delivery	174	161	8%
Electronic Infusion Systems	173	166	5%
Anesthesia	191	181	5%
Other <sup>4</sup>	109	94	15%
<b>Total Medication Delivery <sup>5</sup></b>	<b>\$ 929</b>	<b>\$ 850</b>	<b>9%</b>
<b>Renal</b>			
PD Therapy	\$ 345	\$ 301	15%
HD Therapy	121	103	17%
Other	4	3	66%
<b>Total Renal</b>	<b>\$ 470</b>	<b>\$ 407</b>	<b>16%</b>
<b>TOTAL BAXTER</b>	<b>\$2,209</b>	<b>\$1,997</b>	<b>11%</b>

<sup>1</sup> Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery (Tisseel) and other plasma-based products.

<sup>2</sup> Principally includes vaccines and non-plasma-based biosurgery products (FloSeal and CoSeal)

<sup>3</sup> Principally includes intravenous solutions and nutritional products.

<sup>4</sup> Principally includes oncology and other hospital-distributed products.

<sup>5</sup> Sales of pain management products, which were previously included in Anesthesia, are now reported in either Electronic Infusion Systems or Other, depending on the product. All prior sales data has been reclassified to reflect this change.